Targeting the effector site with IFN-αβ-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1535-1544

  Currie, Andrew J ^a,d   Van Der Most, Robbert G ^a   Broomfield, Steve A ^b   Prosser, Amy C ^a   Tovey, Michael G ^c   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c INSTITUT ANDRÉ LWOFF   (France)

^d National Centre for Asbestos Related Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3M 019; ALPHA INTERFERON; ALPHA INTERFERON BETA; BETA INTERFERON; CPG 1668; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 2216; DOUBLE STRANDED RNA; HEMAGGLUTININ; IMIDAZOQUINOLINE DERIVATIVE; INTERFERON; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; [2,3 BIS(PALMITOYLOXY)PROPYL] N PALMITOYLCYSTEINYLSERYLLYSINE; ANTIVIRUS AGENT; LIGAND; NUCLEIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSAGE SCHEDULE COMPARISON; DRUG TARGETING; ERADICATION THERAPY; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MESOTHELIOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR BLOCKING; SOLID TUMOR; TUMOR IMMUNITY; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; IMMUNITY, NATURAL; INTERFERON-ALPHA; INTERFERON-BETA; LIGANDS; LYMPHOCYTE DEPLETION; MESOTHELIOMA; MICE; MICE, INBRED BALB C; NUCLEIC ACIDS; POLY I-C; RNA, DOUBLE-STRANDED;

EID: 40749159166     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1535     Document Type: Article

References (58)

1. Marzo, A. L., R. A. Lake, D. Lo, L. Sherman, A. McWilliam, D. Nelson, B. W. Robinson, and B. Scott. 1999. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 162: 5838-5845.
2. Nelson, D. J., S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson. 2001. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166: 5557-5566.
3. + T cells in tumor-bearing mice. J. Immunol. 174: 2563-2572.
4. Anderson, M. J., K. Shafer-Weaver, N. M. Greenberg, and A. A. Hurwitz. 2007. Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J. Immunol. 178: 1268-1276.
5. Melief, C. J. 2003. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33: 2645-2654.
6. Gajewski, T. F., Y. Meng, C. Blank, I. Brown, A. Kacha, J. Kline, and H. Harlin. 2006. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145.
7. + CTL to cause tumor eradication. J. Immunol. 173: 6753-6759.
8. Trinchieri, G., and A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7: 179-190.
9. Pasare, C., and R. Medzhitov. 2004. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 6: 1382-1387.
10. Degli-Esposti, M. A., and M. J. Smyth. 2005. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5: 112-124.
11. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515.
12. Schmidt, C. 2006. Immune system's Toll-like receptors have good opportunity for cancer treatment. J. Natl. Cancer Inst. 98: 574-575.
13. Huang, B., J. Zhao, H. Li, K. L. He, Y. Chen, S. H. Chen, L. Mayer, J. C. Unkeless, and H. Xiong. 2005. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65: 5009-5014.
14. Killeen, S. D., J. H. Wang, E. J. Andrews, and H. P. Redmond. 2006. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer 95: 247-252.
15. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
16. Tsung, K., and J. A. Norton. 2006. Lessons from Coley's Toxin. Surg. Oncol. 15: 25-28.
17. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59: 1071-1079.
18. + T cells. Eur. J. Immunol. 22: 1013-1022.
19. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
20. Oehen, S., and K. Brduscha-Riem. 1998. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161: 5338-5346.
21. Gresser, I., M. G. Tovey, M. E. Bandu, C. Maury, and D. Brouty-Boye. 1976. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144: 1305-1315.
22. Gresser, I., F. Belardelli, C. Maury, M. T. Maunoury, and M. G. Tovey. 1983. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158: 2095-2107.
23. hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
24. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J. Immunol. 171: 5051-5063.
25. Durand, V., S. Y. Wong, D. F. Tough, and A. Le Bon. 2006. IFN-α/β-dependent cross-priming induced by specific toll-like receptor agonists. Vaccine 24(Suppl. 2): S2-22-S2-23.
26. + T cell response during cross-priming. J. Immunol. 176: 4682-4689.
27. Lang, K. S., M. Recher, T. Junt, A. A. Navarini, N. L. Harris, S. Freigang, B. Odermatt, C. Conrad, L. M. Ittner, S. Bauer, et al. 2005. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11: 138-145.
28. Saito, T., and M. Gale, Jr. 2007. Principles of intracellular viral recognition. Curr. Opin. Immunol. 19: 17-23.
29. Krug, A., G. D. Luker, W. Barchet, D. A. Leib, S. Akira, and M. Colonna. 2004. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103: 1433-1437.
30. Kurooka, M., and Y. Kaneda. 2007. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 67: 227-236.
31. + regulatory T cells. J. Immunol. 172: 5986-5993.
32. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50.
33. Fujimura, T., S. Nakagawa, T. Ohtani, Y. Ito, and S. Aiba. 2006. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36: 3371-3380.
34. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167: 5247-5253.
35. Stumbles, P. A., R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. Robinson. 2004. Cutting edge: tumor-specific CTL are constitutively crossarmed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J. Immunol. 173: 5923-5928.
36. - tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99: 5561-5566.
37. + T effectors. J. Immunol. 177: 6962-6973.
38. Hill, H. C., T. F. Conway, Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62: 7254-7263.
39. Tormo, D., A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, J. Wenzel, and T. Tuting. 2006. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66: 5427-5435.
40. Heckelsmiller, K., S. Beck, K. Rall, B. Sipos, A. Schlamp, E. Tuma, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32: 3235-3245.
41. Garbi, N., B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861-5869.
42. Oberg, K. 1992. The action of interferon α on human carcinoid tumours. Semin. Cancer Biol. 3: 35-41.
43. McBride, S., K. Hoebe, P. Georgel, and E. Janssen. 2006. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J. Immunol. 177: 6122-6128.
44. Le Bon, A., and D. F. Tough. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14: 432-436.
45. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4: 1009-1015.
46. Kolumam, G. A., S. Thomas, L. J. Thompson, J. Sprent, and K. Murali-Krishna. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202: 637-650.
47. Durand, V., S. Y. Wong, D. F. Tough, and A. Le Bon. 2004. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell Biol. 82: 596-602.
48. Prins, R. M., N. Craft, K. W. Bruhn, H. Khan-Farooqi, R. C. Koya, R. Stripecke, J. F. Miller, and L. M. Liau. 2006. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176: 157-164.
49. Cavalheiro, S., P. A. Dastoli, N. S. Silva, S. Toledo, H. Lederman, and M. C. da Silva. 2005. Use of interferon α in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv. Syst. 21: 719-724.
50. Christmas, T. I., L. S. Manning, M. J. Garlepp, A. W. Musk, and B. W. Robinson. 1993. Effect of interferon-α 2a on malignant mesothelioma. J. Interferon Res. 13: 9-12.
51. Berek, J. S., M. Markman, B. Stonebraker, S. S. Lentz, M. D. Adelson, K. DeGeest, and D. Moore. 1999. Intraperitoneal interferon-α in residual ovarian carcinoma: a phase II gynecologic oncology group study. Gynecol. Oncol. 75: 10-14.
52. Paul, E., I. Muller, H. Renner, R. H. Bodeker, and A. J. Cochran. 2003. Treatment of locoregional metastases of malignant melanomas with radiotherapy and intralesional β-interferon injection. Melonoma Res. 13: 611-617.
53. Halloran, P. F., J. Urmson, P. H. van der Meide, and P. Autenried. 1989. Regulation of MHC expression in vivo. II. IFN-α/γ inducers and recombinant IFN-α modulate MHC antigen expression in mouse tissues. J. Immunol. 142: 4241-4247.
54. Upham, J. W., A. W. Musk, G. van Hazel, M. Byrne, and B. W. Robinson. 1993. Interferon α and doxorubicin in malignant mesothelioma: a phase II study. Aust. N. Z. J. Med. 23: 683-687.
55. Makridis, C., C. Juhlin, G. Akerstrom, K. Oberg, and J. Rastad. 1994. MHC class I and II antigen expression and interferon α treatment of human midgut carcinoid tumors. World J. Surg. 18: 481-486.
56. Kammertoens, T., T. Schuler, and T. Blankenstein. 2005. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med. 11: 225-231.
57. Droemann, D., D. Albrecht, J. Gerdes, A. J. Ulmer, D. Branscheid, E. Vollmer, K. Dalhoff, P. Zabel, and T. Goldmann. 2005. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res. 6: 1.
58. Bohnhorst, J., T. Rasmussen, S. H. Moen, M. Flottum, L. Knudsen, M. Borset, T. Espevik, and A. Sundan. 2006. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20: 1138-1144.